These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 30614396

  • 1. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S, Zhu S, Li XJ, Li S.
    Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
    [Abstract] [Full Text] [Related]

  • 2. Autophagy and Polyglutamine Disease.
    Ren H, Hao Z, Wang G.
    Adv Exp Med Biol; 2020 Oct; 1207():149-161. PubMed ID: 32671744
    [Abstract] [Full Text] [Related]

  • 3. Polyglutamine (PolyQ) diseases: genetics to treatments.
    Fan HC, Ho LI, Chi CS, Chen SJ, Peng GS, Chan TM, Lin SZ, Harn HJ.
    Cell Transplant; 2014 Oct; 23(4-5):441-58. PubMed ID: 24816443
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity.
    Cortes CJ, La Spada AR.
    Adv Exp Med Biol; 2018 Oct; 1049():103-133. PubMed ID: 29427100
    [Abstract] [Full Text] [Related]

  • 8. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN, Eremeev AV, Pozmogova GE, Lagarkova MA.
    Mol Biol (Mosk); 2019 Oct; 53(6):954-967. PubMed ID: 31876275
    [Abstract] [Full Text] [Related]

  • 9.
    Lo DC, Hughes RE, La Spada AR, Weydt P, Pineda VV.
    ; 2011 Oct. PubMed ID: 21882412
    [Abstract] [Full Text] [Related]

  • 10. Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy.
    Pluciennik A, Liu Y, Molotsky E, Marsh GB, Ranxhi B, Arnold FJ, St-Cyr S, Davidson B, Pourshafie N, Lieberman AP, Gu W, Todi SV, Merry DE.
    J Clin Invest; 2021 Jan 04; 131(1):. PubMed ID: 33170804
    [Abstract] [Full Text] [Related]

  • 11. Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects.
    Bonsor M, Ammar O, Schnoegl S, Wanker EE, Silva Ramos E.
    Proteomics; 2024 Jun 04; 24(12-13):e2300114. PubMed ID: 38615323
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.
    Wanker EE.
    Biol Chem; 2000 Jun 04; 381(9-10):937-42. PubMed ID: 11076024
    [Abstract] [Full Text] [Related]

  • 14. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
    Stoyas CA, La Spada AR.
    Handb Clin Neurol; 2018 Jun 04; 147():143-170. PubMed ID: 29325609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
    Ross CA.
    Neuron; 2002 Aug 29; 35(5):819-22. PubMed ID: 12372277
    [Abstract] [Full Text] [Related]

  • 18. Polyglutamine neurodegeneration: expanded glutamines enhance native functions.
    Orr HT.
    Curr Opin Genet Dev; 2012 Jun 29; 22(3):251-5. PubMed ID: 22284692
    [Abstract] [Full Text] [Related]

  • 19. Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability.
    Hashimoto M, Ho G, Takamatsu Y, Wada R, Sugama S, Takenouchi T, Masliah E, Waragai M.
    J Huntingtons Dis; 2018 Jun 29; 7(4):297-307. PubMed ID: 30372687
    [Abstract] [Full Text] [Related]

  • 20. Huntingtin aggregation and toxicity in Huntington's disease.
    Bates G.
    Lancet; 2003 May 10; 361(9369):1642-4. PubMed ID: 12747895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.